Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Amcenestrant vs endocrine monotherapy in ER+/HER2- advanced breast cancer
NCT04059484Phase 2Terminated
- Sponsor
- Sanofi
- Start
- Oct 2019
- Primary completion
- Feb 2022
- Modality
- Small Molecules
- Countries
- 23
01
Overview
A Phase 2 trial of amcenestrant in estrogen receptor-positive breast cancer (ER+), sponsored by Sanofi. Started Oct 2019; status: terminated.
02
Drugs
amcenestrant
03
Conditions
estrogen receptor-positive breast cancer (ER+)
Beyond the preview
Go deeper on NCT04059484.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04059484.